Authors: Puoliväli, Jukka | Nurmi, Antti | Miettinen, Taina-Kaisa | Soleti, Antonio | Riccardino, Francesca | Kalesnykas, Giedrius | Heikkinen, Taneli | Vartiainen, Nina | Pussinen, Raimo | Tähtivaara, Leena | Lehtimäki, Kimmo | Yrjänheikki, Juha | Canistro, Donatella | Sapone, Andrea | Spisni, Enzo | Paolini, Moreno
Article Type:
Research Article
Abstract:
The purpose of this study was to evaluate the efficacy of the radical scavenger IAC (bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl) decantionate) in alleviating behavioral deficits and reducing amyloid-β (Aβ) accumulation in an Alzheimer's disease (AD) transgenic Tg2576 mouse model. Daily treatment with IAC (3–30 mg/kg, i.p.) was started at the age of 6 months and continued until the mice were 13 months old. At the age of 9 months and again at 12 months, the mice were tested in open field and water maze tests. At the age of 13 months, the mice were sacrificed and the brains processed for immunohistochemistry. Mortality was significantly
…reduced in all IAC-treated groups. In addition, IAC treatment improved the water maze hidden platform training performance but had no effect on motor activity in the open field or water maze swim speed in transgenic mice. Lastly, IAC treatment (10 mg/kg) significantly reduced the cortical Aβ plaque burden. In vitro, IAC is able to increase the number of neurites and neurite branches in cultured cortical primary neurons. In conclusion, IAC slowed down the development of the AD-like phenotype in Tg2576 mice and accelerated neurite growth in cultured neurons.
Show more
Keywords: Alzheimer's disease, antioxidant, IAC (bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl) decantionate), Tg2576 mice
DOI: 10.3233/JAD-2011-110881
Citation: Journal of Alzheimer's Disease,
vol. 27, no. 3, pp. 499-510, 2011
Price: EUR 27.50